論文 - 詳細
| RRC ID | 75284 |
|---|---|
| 著者 | Misawa K, Nishimura T, Kashimura S, Enoki Y, Taguchi K, Uno S, Uwamino Y, Matsumoto K, Hasegawa N. |
| タイトル | In vitro effects of diazabicyclooctane β-lactamase inhibitors relebactam and nacubactam against three subspecies of Mycobacterium abscessus complex. |
| ジャーナル | Int J Antimicrob Agents |
| Abstract |
BACKGROUND:Mycobacterium abscessus complex (MABC) pulmonary disease is notoriously difficult to treat due to intrinsic resistance to many common antibiotics. MABC is β-lactam-resistant as it produces class A β-lactamases, such as blaMab, which are inhibited by diazabicyclooctane (DBO) β-lactamase inhibitors. OBJECTIVES:To investigate the microbiological effects of the combination of β-lactam and DBO β-lactamase inhibitors (relebactam and nacubactam) against MABC and determine if the effects are associated with the MABC subspecies and colony morphotype. METHODS:The antimicrobial susceptibility of three type strains and 20 clinical isolates of MABC to the combination of seven β-lactams with relebactam or nacubactam was evaluated using broth microdilution checkerboard assays. For these strains, expression levels of blaMab were assessed using quantitative real-time polymerase chain reaction and genotypic diversity was evaluated using 18-locus variable number tandem repeat assay. RESULTS:Relebactam and nacubactam lowered the minimum inhibitory concentrations of β-lactams, particularly imipenem, meropenem, and tebipenem, against MABC. There was no difference in efficacy of combination treatment between three subspecies, but rough morphotypes tended to be less susceptible than smooth morphotypes. There were no differences in blaMab expression levels and genotypic diversity between the morphotypes. CONCLUSIONS:The combination of β-lactam with relebactam or nacubactam improved the efficacy of β-lactams against all MABC subspecies, but higher concentrations of β-lactams were needed for rough morphotypes. |
| 巻・号 | 60(5-6) |
| ページ | 106669 |
| 公開日 | 2022-1-1 |
| DOI | 10.1016/j.ijantimicag.2022.106669 |
| PII | S0924-8579(22)00189-3 |
| PMID | 36064079 |
| MeSH | Anti-Bacterial Agents / pharmacology Anti-Bacterial Agents / therapeutic use Azabicyclo Compounds / therapeutic use Microbial Sensitivity Tests Mycobacterium abscessus* beta-Lactamase Inhibitors* / therapeutic use beta-Lactamases / metabolism beta-Lactams / pharmacology |
| リソース情報 | |
| 一般微生物 | JCM 13569 JCM 15300 JCM 15297 |